Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

BACKGROUND: Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is generally an incurable disease, with patients experiencing median survival of under 10 months and significant morbidity. While immune checkpoint blockade (ICB) drugs are effective in approximately 20% of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Valero, Cristina, Golkaram, Mahdi, Vos, Joris L., Xu, Bin, Fitzgerald, Conall, Lee, Mark, Kaplan, Shannon, Han, Catherine Y., Pei, Xin, Sarkar, Reith, Boe, Lillian A., Pandey, Abhinav, Koh, Elizabeth S., Zuur, Charlotte L., Solit, David B., Pawlowski, Traci, Liu, Li, Ho, Alan L., Chowell, Diego, Riaz, Nadeem, Chan, Timothy A., Morris, Luc G.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541199/
https://www.ncbi.nlm.nih.gov/pubmed/37561583
http://dx.doi.org/10.1172/JCI169823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541199/
https://www.ncbi.nlm.nih.gov/pubmed/37561583
http://dx.doi.org/10.1172/JCI169823

Ejemplares similares